Key result
Higher eGFR is linked to ~2% lower in-hospital NACE risk after PCI for NSTE-ACS.
Why the study?
The efficacy of different estimated glomerular filtration rate (eGFR) formulas for predicting prognosis in NSTE-ACS patients receiving PCI is unknown.
Cohort (n=2,159)
Yes
Odds Ratio: 0.98 (95% CI 0.97–1)
p-value: p=0.012
Supports eGFR as prognostic marker for in-hospital NACE post-PCI in NSTE-ACS regardless of formula; hypothesis-generating, should not yet change practice.
BACKGROUND: The relationships of renal dysfunction (RD) and chronic kidney disease (CKD) with prognosis have been well established among non-ST elevation acute coronary syndrome (NSTE-ACS) patients who receive percutaneous coronary intervention (PCI), but the efficacy of different estimated glomerular filtration rate (eGFR) formulas for predicting the prognosis is unknown. METHODS: The cohort originated from a retrospective data, which consecutively enrolled 8197 patients. The eGFR was calculated by the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), CKD Epidemiology Collaboration-creatinine, CKD Epidemiology Collaboration-Cys-C, CKD Epidemiology Collaboration-Cys-C-creatinine and a modified abbreviated MDRD (c-aGFR) equations in Chinese CKD patients. Patients were excluded if the eGFR could not be obtained by one of the formulas. Patients were categorized as having normal renal function, mild RD, moderate RD, severe RD, or kidney failure to compare prognosis. The primary outcome was the in-hospital net adverse clinical events (NACE). The secondary outcomes were NACE and all-cause death during follow-up. RESULTS: In total, 2159 NSTE-ACS patients (age: 64.23 ± 10.25 years; males: 73.7%) were enrolled. 39 (1.8%) patients with in-hospital NACE were observed. During the 3.23 ± 1.55-year follow-up, 1.7% death and 4.2% NACE were observed in 1 year. The percentage of severe RD patients ranged from 15.4 to 39.2% according to different calculation formulas. A high prevalence of in-hospital NACE was observed in the severe RD groups (ranging from 8 to 14.3% for different formulas). Multiple regression analysis showed that a high eGFR is a protect factor against NACE and all-cause death regardless of the formula use. Receiver operating characteristic curves showed similar predictive performance of the c-aGFR when compared to other formulas (in-hospital NACE: AUC = 0.612, follow-up NACE: AUC = 0.622, and follow-up death: AUC = 0.711). CONCLUSIONS: Severe RD results in a high prevalence of in-hospital NACE in NSTE-ACS patients after PCI regardless of the formulas use. Different formulas have a similar ability to predict in-hospital and long-term prognosis in NSTE-ACS patients. The c-aGFR formula is the simplest and a more convenient formula for use in practice.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a cohort in Non-ST elevation acute coronary syndrome (NSTE-ACS) undergoing PCI (n=2,159). Estimated glomerular filtration rate (eGFR) vs. Lower eGFR was evaluated on In-hospital net adverse clinical events (NACE) (OR 0.98, 95% CI 0.97-1.00, p=0.012). Higher estimated glomerular filtration rate was associated with a reduced risk of in-hospital net adverse clinical events (OR 0.98) regardless of the formula used in NSTE-ACS patients after PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: